Indication intelligence, analysis and sector perception

RegMed’s close: the need to recoup losses is greater than ever

October 26, 2015 6:27pm

The issue is finding support levels for optimism to return and vulnerability to diminish

Uncertainty creates volatility and diminished expectation. Subscription required: http://www.regmedinvestors.com/user/register , read more …

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

U.S. stocks closed narrowly mixed Monday, holding most of last week's gains, as investors readied for another week of earnings and central bank announcements.

The NASDAQ closed UP +2.84 or +0.06% to 5,034.70 and the DOW closed DOWN -23.65 or -0.13% to 17,623.05.

Henry’omics:

The stem, cell, gene therapy and regenerative medicine (SCGT&RM) stocks rode the roller coaster through-out the day to close negative.

But, the iShares Nasdaq Biotechnology ETF (IBB) closed up 0.4%.

Despite the decline in the SCGT&RM sector; one of my indicators – the Advance/Decline Line <A/DL> opened at 13/28 and closed at 14/28 having been down 6/37 at the first half-hour of the session.

We're going to need catalysts and actionable news flow to move us forward!

The sector’s venue: “Veniremus, emimus, vendidit” – the new mantra, we came, we bought, we sold!

Riding the indexes and ETFs roller-coaster:

The iShares Biotechnology Stocks ETF (IBB) closed UP on Monday +1.17 or +0.37% following Friday’s advance of +10.17 or +3.32%;

The NASDAQ Biotechnology index (NBI) closed UP Monday +27.14 or +0.82% following Friday’s +91.69 or +2.86%;

The Russell 2000 (IWM) closed DOWN on Monday -0.79 or -0.68% following Friday’s advance of + 1.13 or +0.99%;

The SPDR SD&P Biotech ETF (XBI) closed UP on Monday +0.20 or +0.30% following Friday’s advance of +1.50 or +2.34%

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

The SCGT & RM equities opened negative with an A/DL of 13/28 and 3 flats dropping to a precipitous negative first half hour A/DL’ of 6/37 and 0 flats jumping to positive first hour of an A/DL of 22/19 and 0 flats;

The session dived to a negative second hour (11:30 am) with an A/DL of 19/24 and 0 flats building to a positive mid-day A/DL of 23/20 and 0 flat;

The closing bell synched positive to end the session with an A/DL of 14/28 and 1 flat.

Fluctuation in volume is still a concern which relates to sentiment and company expectation,

My fear index, the CBOE Volatility Index (VIX) traded near 15 on Monday following Friday’s near 14.

Dosing the sector – what a day for the 43 Patients:

Open: NEGATIVE with 28 decliners, 13 advances and 2 flats;

Mid-day (12:30 pm): POSITIVE with 20 decliners, 23 advancers and 0 flat;

Closing bell: NEGATIVE with 28 decliners, 14 advancers and 1 flat

Monday’s trading indications: 4 hits/ 6 misses:

Applied Genetic Technologies (AGTC) closed DOWN – miss;
Capricor (CAPR) closed UP – miss;
Caladrius Biosciences (CLBS) <formerly NeoStem (NBS)> closed FLAT- miss;
Intrexon (XON) closed DOWN – hit;
Juno Therapeutics (JUNO) closed UP – miss;
Kite Pharma (KITE) closed DOWN – hit;
Sangamo Biosciences (SGMO) closed DOWN – miss;
Spark Therapeutics (ONCE) closed DOWN – hit;
uniQure (QURE) closed DOWN – miss;
Verastem (VSTM) closed UP – hit;

Who is down – top 5?

Spark Therapeutics (ONCE) was down $1.91 to $59.90;
Kite Pharma (KITE) -$0.94 to $69.67;
Histogenics (HSGX) -$0.64 to $3.85;
uniQure (QURE) -$0.57 to $17.39;
Sangamo (SGMO) was down -$0.38 to $6.81

Who was UP?

VistaGen (VSTA) was up+$0.99 to $7.99;
Aduro Biotech (ADRO) is up +$0.54 to $24.68;
Juno therapeutics (JUNO) is up +$1.28 to $50.46;
Regenxbio (RGNX) +$0.55 to $14.70;
MiMedx (MDXG) is up +40.15 to $9.03

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.